Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape
The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that will start in the middle of the year.
You may also be interested in...
Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
Nektar/Bristol Show Promise With Double IO Combo, But Numbers Are Small
Updated data from PIVOT-02 at the ASCO GU meeting suggest a path for accelerated approval of the NKTR-214/Opdivo combination as first-line treatment of patients with PD-L1-negative urothelial cancers.
A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
The cancer immunotherapy combo showed "remarkable" effects in patients who tested negative for PD-L1 expression and would normally not respond well to immunotherapy.